Peer-reviewed veterinary case report
CT scan tumor size changes after liver cancer chemoembolization
By Rogatko, Cleo et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2023·Royal (Dick) School of Veterinary Studies, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of computed tomography response criteria after chemoembolization of hepatic carcinoma in dogs.
- Species:
- dog
Plain-English summary
A group of 16 dogs with liver cancer that couldn't be surgically removed underwent a treatment called drug-eluting bead transarterial-chemoembolization (DEB-TACE). Researchers used CT scans to measure the tumors before and after treatment to see how well the dogs responded and how long they might live afterward. They found that while certain measurements of the tumors could indicate a shorter survival time, the overall response to treatment didn't directly correlate with how long the dogs lived. This suggests that while imaging can provide some insights, it may not be the best predictor of survival for dogs with this type of cancer.
People also search for: dog liver cancer treatment · DEB-TACE for dogs · dog CT scan results liver cancer · how long can a dog live with liver cancer
Abstract
The objective of this study was to evaluate unidimensional (mm), bidimensional (mm), or tridimensional (mL) computed tomography (CT) tumor measurements for ability to discriminate changes in lesion size and predict survival in dogs with nonresectable hepatic carcinoma treated with drug-eluting bead transarterial-chemoembolization (DEB-TACE) and to compare CT responseResponse Evaluation Criteria in Solid Tumors 1.1 (mm), World Health Organization (mm), ellipsoid and spherical volume (mL), and percent necrosis, for their ability to differentiate treatment responders. This was a prospective, single-arm clinical trial. DEB-TACE was performed to varying levels of blood flow stasis in 16 client-owned dogs with nonresectable hepatic carcinoma. Computed tomography imaging responses were assessed and compared to median survival time. Results revealed that initial, follow-up, or changes in unidimensional, bidimensional, or tridimensional tumor measurements were not associated with survival. Larger bidimensional and tridimensional tumor measurements/body weight on initial and follow-up CT were significantly associated with a shorter median survival time [bidimensional (= 0.04, 0.016) and tridimensional (= 0.025, 0.015), respectively]. A higher percent necrosis on initial CT was significantly associated with a shorter median survival time (= 0.038). Ellipsoid volumetric criteria detected treatment response most frequently; however, response classification was not associated with median survival time. Computed tomography bidimensional and tridimensional tumor measurements/body weight before and after DEB-TACE may help to predict median survival time for dogs undergoing DEB-TACE for hepatic carcinoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36606034/